Arvinas, Inc. (ARVN) stock
ARVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$6.82+0.05 (+0.74%)
Close on Nov 17, 2026Market cap $445.93MP/E 42.6Yield –
Arvinas price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Arvinas's price to sales ratio was 1.4× on Nov 11, 2026, against 2.9× a year earlier. Over the last 5 years it ranged from 1.2× to 196.0×, with a median of 11.1×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 1.4× | −1.3 |
| 2025 | Dec 31, 2025 | 2.7× | −11.6 |
| 2024 | Jan 31, 2024 | 14.3× | +0.1 |
| 2023 | Dec 29, 2023 | 14.2× | −0.2 |
| 2022 | Dec 30, 2022 | 14.4× | −148.5 |
| 2021 | Dec 31, 2021 | 162.8× | +23.7 |
| 2020 | Dec 31, 2020 | 139.1× | +106.4 |
| 2019 | Dec 31, 2019 | 32.7× | +29.2 |
| 2018 | Dec 31, 2018 | 3.5× | – |
See a number that looks wrong?